fda bpc 157 unapproved drug warning letter Peptides like BPC-157 and TB-500 are blowing up online for injury recovery, but they’re not FDA-approved and they’re in a legal gray area. The end of July, an advisory committee meets to weigh in BPC-157 Legal Status: FDA Regulations

Consistency over weeks matters more than perfect daily adherence

It is, however, unknown whether the depolarization requirement often observed for unblocking NMDA receptors is necessary for activation of presynaptic NMDA receptors, since GluN2C/D and GluN3A-containing NMDA receptors show less voltage sensitivity than other NMDA receptor types (Cull-Candy et al., 2001

Cortex 32 (3), 467478 (2022)

Leaders should proactively model: Gross margin sensitivity Program pricing flexibility Inventory risk exposure Cash flow implications 5

There always could be a lot of hype. Why the FDA and Health Canada Are Warning About Peptides Two regulatory actions are driving the current conversation: FDA (2023): Placed restrictions on peptides sold by compounding pharmacies in the United States, citing concerns about safety, purity, and lack of FDA approval for many compounds